Please ensure Javascript is enabled for purposes of website accessibility

Novartis Shuts Down Hydroxychloroquine COVID-19 Clinical Trial

By Eric Volkman – Jun 22, 2020 at 4:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The move hastens the demise of the malaria drug as a potential treatment for the disease.

The rapid descent continues for hydroxychloroquine as hope for a cure for COVID-19. On Monday, pharmaceutical giant Novartis (NVS -0.73%) announced that it is stopping the sponsored clinical trial it was conducting on the treatment of COVID-19 with the drug.

The company says this is "due to acute enrollment challenges that have made trial completion infeasible." It stressed that no safety issues had been reported from the study. On the other hand, it reached no conclusions on the drug's efficacy.

Drawing of magnified coronavirus particles

Image source: Getty Images.

First introduced in the 1950s to treat malaria, hydroxychloroquine was seen early in the coronavirus outbreak as a potential treatment for COVID-19 following a relatively limited study in France. It was then granted emergency use authorization -- since withdrawn -- by the U.S. Food and Drug Administration (FDA) for certain instances of the disease. President Donald Trump even claimed that he had taken it for preventative purposes.

The results of larger studies, however, indicate that the drug is not effective against COVID-19, and in fact can produce significant fatalities.

The Novartis decision comes less than a week after the World Health Organization (WHO) halted its own hydroxychloroquine COVID-19 study. In the U.S., the National Institutes of Health (NIH) followed suit shortly thereafter.

In the press release on its cessation, Novartis said that it will continue to provide hydroxychloroquine for ongoing studies conducted by both private and public entities "where certain conditions are met and the medicine is used in accordance with a nationally endorsed treatment protocol."

On Monday, Novartis's shares dipped by nearly 0.6%, in contrast to the gains enjoyed by the broader stock market.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novartis AG Stock Quote
Novartis AG
$76.01 (-0.73%) $0.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.